The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Veracyte Inc shares valued at $233,133 were sold by Stapley Marc on Sep 04 ’25. At $30.41 per share, Stapley Marc sold 7,667 shares. The insider’s holdings dropped to 334,185 shares worth approximately $11.1 million following the completion of this transaction.
Also, MARC STAPLEY purchased 7,667 shares, netting a total of over 234,764 in proceeds.
Before that, EASTHAM KARIN had sold 4,590 shares from its account. In a trade valued at $122,388, the Director traded Veracyte Inc shares for $26.66 each. Upon closing the transaction, the insider’s holdings decreased to 4,590 shares, worth approximately $0.46 million.
As published in their initiating research note from Craig Hallum on March 20, 2025, Veracyte Inc [VCYT] has been a Buy and the price target has been revised to $45. Analysts at Goldman downgraded the stock from ‘”a Buy”‘ to ‘”a Neutral”‘ outlook in a report released in early December. As of November 15, 2024, Wolfe Research has initiated its “an Outperform” rating for VCYT. Earlier on October 16, 2024, UBS initiated its rating. Their recommendation was “a Buy” for VCYT stock.
Analyzing VCYT Stock Performance
On last trading session, Veracyte Inc [NASDAQ: VCYT] rose 4.40% to $33.23. The stock’s lowest price that day was $32.09, but it reached a high of $33.35 in the same session. During the last five days, there has been a surge of approximately 4.30%. Over the course of the year, Veracyte Inc shares have dropped approximately -1.19%.
Is Veracyte Inc subject to short interest?
Stocks of Veracyte Inc saw a sharp steep in short interest on 2025-08-29 dropping by -1.03 million shares to 8.04 million. Data from Yahoo Finance shows that the short interest on 2025-07-31 was 9.08 million shares. A decline of -12.86% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 5.71 of the overall float, the days-to-cover ratio (short ratio) decline to 5.71.
Which companies own the most shares of Veracyte Inc (VCYT)?
In terms of Veracyte Inc share price expectations, FactSet research, analysts set an average price target of 28 in the next 12 months, down nearly -12.03% from the previous closing price of $31.83. Analysts anticipate Veracyte Inc stock to reach 28 by 2025, with the lowest price target being 28. In spite of this, 0 analysts ranked Veracyte Inc stock as nan at the end of 2025. On October 10, 2024, Guggenheim assigned a price target of “a Buy” to the stock and initiated coverage with a $40.
